Clinical TrialJun 24, 2026, 08:31 AM
Wave Life Sciences Initiates WVE-007 Phase 2a; Phase 1 Shows 14% Visceral Fat Loss
AI Summary
Wave Life Sciences announced the initiation of the Phase 2a multidose portion of its INLIGHT trial for WVE-007, an investigational GalNAc-siRNA for obesity. This portion will evaluate WVE-007 as a monotherapy in individuals with high BMI and comorbidities. The company also reported positive six-month follow-up data from the Phase 1 single-dose portion, showing clinically meaningful reductions in visceral fat (-14%), total fat (-5%), and waist circumference (-3%) with a single 240 mg dose, supporting once or twice-yearly dosing. Wave plans to initiate additional Phase 2 trials for WVE-007 in 2H 2026.
Key Highlights
- Initiated Phase 2a multidose portion of INLIGHT trial for WVE-007 in obesity.
- Phase 1 data showed 14% visceral fat reduction at 6 months with single 240 mg dose.
- Phase 1 data also showed 5% total fat reduction and 3% waist circumference reduction.
- WVE-007 demonstrated potential for once or twice-yearly dosing.
- Phase 2a targets individuals with higher BMI (35-50 kg/m2) and comorbidities.
- Additional Phase 2 trials for WVE-007 planned for 2H 2026.
Price Impact
More from WVE